BOCH
ENGN icon

Blue Owl Capital Holdings’s enGene Therapeutics ENGN Stock Holding History

Blue Owl Capital Holdings’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,416,353
Closed -$30.1M – 80
2026
Q1 		$30.1M Buy
4,416,353
+1,055,416
+31% +$9.4M 8.08% 3
2025
Q4 		$30.3M Buy
3,360,937
+82,831
+3% +$664K 9.37% 1
2025
Q3 		$22.4M Sell
3,278,106
-450,000
-12% -$2.05M 6.95% 3
2025
Q2 		$13.6M Buy
3,728,106
+448,728
+14% +$1.68M 4.38% 7
2025
Q1 		$14.7M Buy
3,279,378
+119,403
+4% +$742K 4.74% 7
2024
Q4 		$21M Buy
3,159,975
+101,006
+3% +$784K 4.84% 8
2024
Q3 		$20.2M Buy
3,058,969
+609,142
+25% +$4.53M 3.89% 9
2024
Q2 		$23.1M Sell
2,449,827
-11,523
-0.5% -$148K 6.43% 6
2024
Q1 		$41.7M Buy
2,461,350
+1,226,590
+99% +$15M 8.33% 4
2023
Q4 		$11.4M Buy
+1,234,760
New +$10.9M 2.72% 12

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Blue Owl Capital Holdings's ENGN Position: Q2 2026 in Review

Blue Owl Capital Holdings sold out of enGene Therapeutics (ENGN) in Q2 2026, closing a stake of 4,416,353 shares — an estimated $30.1M sold.

Blue Owl Capital Holdings first reported a position in ENGN in Q4 2023 and held it in 10 quarters. The position peaked at $41.7M in Q1 2024. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Blue Owl Capital Holdings reported no remaining enGene Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Blue Owl Capital Holdings sold 4,416,353 enGene Therapeutics shares in Q2 2026, an estimated $30.1M.
  • Blue Owl Capital Holdings first reported a position in enGene Therapeutics in Q4 2023 and held it in 10 quarters.
  • Blue Owl Capital Holdings's enGene Therapeutics position peaked at $41.7M in Q1 2024.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q2 2026, filed 11 Aug 2026.